CGCHealthcare · Drug Manufacturers - Specialty & GenericThe 8 Wall Street analysts covering Canopy Growth Corp. hold a median 12-month price target of $1.19 — +44.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 9 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Canopy Growth Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (70): Analysts have, on balance, been raising their forecasts.
Momentum (10): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CGC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +44.2% from it.
Of the 20 most recent actions, 4 moved their price target up and 11 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2025 | Benchmark | Upgrade | Hold | — |
| 27 Mar 2025 | Zuanic & Associates | Initiates | Neutral | — |
| 9 July 2024 | Piper Sandler | Maintains | Underweight | — |
| 15 Sept 2023 | B of A Securities | Maintains | Underperform | $0.56 → $0.66 |
| 12 June 2023 | CIBC | Maintains | Underperformer | $1.75 → $0.50 |
| 2 May 2023 | Piper Sandler | Maintains | Underweight | $2.00 → $1.00 |
| 17 Feb 2023 | Cantor Fitzgerald | Maintains | Neutral | $3.30 → $3.20 |
| 7 Nov 2022 | Cantor Fitzgerald | Maintains | Neutral | $3.05 → $3.30 |
| 2 Nov 2022 | Bernstein | Initiates | Underperform | $1.50 |
| 26 Oct 2022 | Cantor Fitzgerald | Maintains | Neutral | $2.90 → $3.05 |
| 30 Sept 2022 | Barclays | Maintains | Underweight | $3.50 → $2.00 |
| 8 Aug 2022 | Piper Sandler | Maintains | Underweight | $3.00 → $2.50 |
| 30 June 2022 | Piper Sandler | Maintains | Underweight | $4.00 → $3.00 |
| 8 June 2022 | Barclays | Maintains | Underweight | $6.00 → $3.50 |
| 31 May 2022 | Piper Sandler | Maintains | Underweight | $6.00 → $4.00 |
| 22 Mar 2022 | Barclays | Downgrade | Underweight | — |
| 1 Mar 2022 | Barclays | Maintains | Equal-Weight | $14 → $9.00 |
| 18 Feb 2022 | Cantor Fitzgerald | Maintains | Neutral | $9.60 → $11 |
| 22 Dec 2021 | B of A Securities | Downgrade | Underperform | $19 → $10 |
| 20 Dec 2021 | Piper Sandler | Downgrade | Underweight | $11 → $7.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, Canopy Growth Corp. returned −49.9% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 63% of US stocks
Cheaper than 79% of US stocks
Cheaper than 86% of US stocks
Higher than 58% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 7% of US stocks
Higher than 24% of US stocks
Higher than 33% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Canopy Growth Corp. has a market value of $371.6M and an enterprise value of $218.2M.
Revenue in the twelve months to 30 June 2026: $293.6M. The latest quarter grew 12.5% year on year.
Net income over the same four quarters: −$236.0M, a −80.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.62.
Free cash flow in the twelve months to 30 June 2026: −$83.7M.
Trailing P/E: −0.9×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Canopy Growth Corp. employs 1,128 people — $260K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Canopy Growth Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article compares Canopy Growth’s focus on medical and adult-use markets and its U.S. expansion strategy through Canopy USA with Tilray Brands’ cannabis operations and diversified craft beer and beverage portfolio.
Why it matters — CGC watchers may find the comparison useful for understanding how the two companies’ business focuses and revenue sources differ.
Tilray Brands reported record Q1 FY2027 revenue, but its cannabis sales declined and its shares fell 4%. Canopy Growth and Aurora Cannabis also eased, according to the headline.
Why it matters — The report groups Canopy Growth with other cannabis stocks that eased amid investor reaction to Tilray’s shrinking cannabis sales despite record revenue.
Canopy Growth Corporation (CGC) closed the recent trading session at $0.87, down 1.87% from the prior day's close. The headline says the decline exceeded the broader market's move.
Why it matters — CGC watchers may note the session's decline and its comparison with the broader market.
A Motley Fool article asks whether Canopy Growth can survive another five years, citing significant cash burn last quarter and poor financials as key reasons the stock has cratered.
Why it matters — The company's cash use and financial condition are relevant to CGC watchers assessing its ability to continue operating.
Canopy Growth Corporation's stock fell 1.54% in the latest trading day, closing at $0.88, even though the broader market improved. Zacks Investment Research reported the decline.
Why it matters — A CGC watcher would note the stock's decline against a rising market, signaling company-specific pressure separate from overall market conditions.
The 8 Wall Street analysts covering Canopy Growth Corp. have a median 12-month price target of $1.19, with estimates ranging from $1.19 to $1.19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Canopy Growth Corp., 2 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Canopy Growth Corp. 42 out of 100 across roughly 4,600 US stocks as at 9 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 9 Oct 2026, Canopy Growth Corp. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (70 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +44.2% from the last close, and Ticker Nerd's factor model ranks Canopy Growth Corp. 42 out of 100 as at 9 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Canopy Growth Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.19 to $1.19 over the next 12 months.
Canopy Growth Corp. returned -49.9% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Canopy Growth Corporation is a Canadian cannabis company focused on the production, distribution, and sale of cannabis and cannabis-related products for medical and adult-use markets. Its business spans a range of product categories, including dried flower, oils, softgels, infused pre-rolls, and vaporizers, supported by brands such as Tweed, Doja, LivRelief, Ace Valley, and Deep Space.
The most recent item we track (The Motley Fool, 10 Oct 2026): "Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?". The article compares Canopy Growth’s focus on medical and adult-use markets and its U.S. expansion strategy through Canopy USA with Tilray Brands’ cannabis operations and diversified craft beer and beverage portfolio.
Canopy Growth Corporation is a Canadian cannabis company focused on the production, distribution, and sale of cannabis and cannabis-related products for medical and adult-use markets. Its business spans a range of product categories, including dried flower, oils, softgels, infused pre-rolls, and vaporizers, supported by brands such as Tweed, Doja, LivRelief, Ace Valley, and Deep Space. The company operates through its Cannabis and Storz & Bickel segments, serving customers in Canada and selected international markets, including Europe and Germany. Canopy Growth also maintains a presence in medical cannabis and related wellness products, with an emphasis on regulated supply chains, branded consumer offerings, and international compliance capabilities. Headquartered in Smiths Falls, Ontario, Canopy Growth plays a notable role in the global cannabis market as a diversified producer and distributor with both medical and consumer-focused product lines.
CEO Mr. Luc Mongeau · 1,128 employees · Canada · https://www.canopygrowth.com
